These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 21187117)
21. Serological cross-reactivity between Merkel cell polyomavirus and two closely related chimpanzee polyomaviruses. Nicol JT; Liais E; Potier R; Mazzoni E; Tognon M; Coursaget P; Touzé A PLoS One; 2014; 9(5):e97030. PubMed ID: 24816721 [TBL] [Abstract][Full Text] [Related]
22. Specific antibodies reacting with simian virus 40 capsid protein mimotopes in serum samples from healthy blood donors. Corallini A; Mazzoni E; Taronna A; Manfrini M; Carandina G; Guerra G; Guaschino R; Vaniglia F; Magnani C; Casali F; Dolcetti R; Palmonari C; Rezza G; Martini F; Barbanti-Brodano G; Tognon MG Hum Immunol; 2012 May; 73(5):502-10. PubMed ID: 22387152 [TBL] [Abstract][Full Text] [Related]
23. Development and Evaluation of a Broad Bead-Based Multiplex Immunoassay To Measure IgG Seroreactivity against Human Polyomaviruses. Kamminga S; van der Meijden E; Wunderink HF; Touzé A; Zaaijer HL; Feltkamp MCW J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29305551 [TBL] [Abstract][Full Text] [Related]
24. Size and position of truncations in the carboxy-terminal region of major capsid protein VP1 of hamster polyomavirus expressed in yeast determine its assembly capacity. Gedvilaite A; Aleksaite E; Staniulis J; Ulrich R; Sasnauskas K Arch Virol; 2006 Sep; 151(9):1811-25. PubMed ID: 16575481 [TBL] [Abstract][Full Text] [Related]
25. Mutational analysis of the carboxyl-terminal region of the SV40 major capsid protein VP1. Yokoyama N; Kawano MA; Tsukamoto H; Enomoto T; Inoue T; Takahashi RU; Nakanishi A; Imai T; Wada T; Handa H J Biochem; 2007 Feb; 141(2):279-86. PubMed ID: 17283011 [TBL] [Abstract][Full Text] [Related]
26. Immunotherapeutic polyoma and human papilloma virus-like particles. Ramqvist T; Dalianis T Immunotherapy; 2009 Mar; 1(2):303-12. PubMed ID: 20635947 [TBL] [Abstract][Full Text] [Related]
27. Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. Inoue T; Kawano MA; Takahashi RU; Tsukamoto H; Enomoto T; Imai T; Kataoka K; Handa H J Biotechnol; 2008 Mar; 134(1-2):181-92. PubMed ID: 18243389 [TBL] [Abstract][Full Text] [Related]
28. Chimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice. Voronkova T; Grosch A; Kazaks A; Ose V; Skrastina D; Sasnauskas K; Jandrig B; Arnold W; Scherneck S; Pumpens P; Ulrich R Viral Immunol; 2002; 15(4):627-43. PubMed ID: 12513932 [TBL] [Abstract][Full Text] [Related]
29. A single vaccination with polyomavirus VP1/VP2Her2 virus-like particles prevents outgrowth of HER-2/neu-expressing tumors. Tegerstedt K; Lindencrona JA; Curcio C; Andreasson K; Tullus C; Forni G; Dalianis T; Kiessling R; Ramqvist T Cancer Res; 2005 Jul; 65(13):5953-7. PubMed ID: 15994974 [TBL] [Abstract][Full Text] [Related]
30. Purification of recombinant trichodysplasia spinulosa-associated polyomavirus VP1-derived virus-like particles using chromatographic techniques. Zaveckas M; Goda K; Ziogiene D; Gedvilaite A J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Jul; 1090():7-13. PubMed ID: 29778875 [TBL] [Abstract][Full Text] [Related]
31. Seroepidemiology of the newly found trichodysplasia spinulosa-associated polyomavirus. Chen T; Mattila PS; Jartti T; Ruuskanen O; Söderlund-Venermo M; Hedman K J Infect Dis; 2011 Nov; 204(10):1523-6. PubMed ID: 21926381 [TBL] [Abstract][Full Text] [Related]
32. Encapsulation of DNA and non-viral protein changes the structure of murine polyomavirus virus-like particles. Lipin DI; Chuan YP; Lua LH; Middelberg AP Arch Virol; 2008; 153(11):2027-39. PubMed ID: 18979257 [TBL] [Abstract][Full Text] [Related]
33. Simian virus 40 (SV40) and human cancer: a review of the serological data. Shah KV; Galloway DA; Knowles WA; Viscidi RP Rev Med Virol; 2004; 14(4):231-9. PubMed ID: 15248251 [TBL] [Abstract][Full Text] [Related]
34. Detection and characterization of a novel polyomavirus in wild rodents. Orba Y; Kobayashi S; Nakamura I; Ishii A; Hang'ombe BM; Mweene AS; Thomas Y; Kimura T; Sawa H J Gen Virol; 2011 Apr; 92(Pt 4):789-95. PubMed ID: 21177925 [TBL] [Abstract][Full Text] [Related]
35. Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs. Tegerstedt K; Andreasson K; Vlastos A; Hedlund KO; Dalianis T; Ramqvist T J Gen Virol; 2003 Dec; 84(Pt 12):3443-3452. PubMed ID: 14645925 [TBL] [Abstract][Full Text] [Related]
36. Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration. Fric J; Marek M; Hrusková V; Holán V; Forstová J Vaccine; 2008 Jun; 26(26):3242-51. PubMed ID: 18468739 [TBL] [Abstract][Full Text] [Related]
38. The optimized capsid gene of porcine circovirus type 2 expressed in yeast forms virus-like particles and elicits antibody responses in mice fed with recombinant yeast extracts. Bucarey SA; Noriega J; Reyes P; Tapia C; Sáenz L; Zuñiga A; Tobar JA Vaccine; 2009 Sep; 27(42):5781-90. PubMed ID: 19664739 [TBL] [Abstract][Full Text] [Related]
39. Role of the C-terminal region of vervet monkey polyomavirus 1 VP1 in virion formation. Yamaguchi H; Kobayashi S; Maruyama J; Sasaki M; Takada A; Kimura T; Sawa H; Orba Y J Vet Med Sci; 2014 May; 76(5):637-44. PubMed ID: 24419975 [TBL] [Abstract][Full Text] [Related]
40. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer. Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]